ARTICLE | Company News
Boehringer Ingelheim, Centrexion Therapeutics deal
April 4, 2016 7:00 AM UTC
Centrexion acquired from Boehringer pain compounds CNTX-6970, CNTX-6016 and CNTX-0290. CNTX-6970, a selective cytokine CC chemokine receptor 2 ( CCR2; CD192) antagonist, is in Phase I testing to ...